Ora, Inc. Partners with the North West London Clinical Trials Alliance to Accelerate Patient Access to Cutting-Edge Ophthalmology Treatments
Ora, Inc., the world’s leading Clinical Research Organization (CRO) for ophthalmology pharmaceutical and device development, announced today its partnership with the North West London Clinical Trials Alliance (NWL Clinical Trials Alliance), a collaboration between clinical trial teams that aims to improve access to and the quality of clinical research in the region.
This strategic partnership comes at a pivotal time as the UK government emphasizes the importance of innovative partnerships and encourages increased, multi-sector collaboration. The partnership between Ora and the NWL Clinical Trials Alliance directly supports this initiative bringing together academia, industry and the NHS to provide better solutions that will address the gap in patient-access to cutting-edge treatment options.
“Ora and the NWL Clinical Trials Alliance share a common goal: improve access to, and the quality of, clinical research in Europe,” said Stuart Abelson, CEO Ora. “Ora’s well-established leadership position in ophthalmology research, coupled with the reach and relationships established by the NWL Clinical Trials Alliance, will provide our sponsors with an increased level of confidence to deliver European-based early and late-phase research studies.”
For sponsors planning or considering trial delivery in Europe, Ora and the NWL Clinical Trials Alliance will provide:
- Comprehensive analysis of country and site selection, that includes candid feedback based on open and honest communication with study sites.
- Access to a diverse group of study participants eager to receive new treatment options.
- Operational excellence delivered by a seasoned team of ophthalmology-focused resources committed to delivering trials with speed, efficiency, quality, and cost-savings.
“We are honoured to partner with a globally recognized leader in ophthalmology research,” said Dr Suki Balendra, director of NWL Clinical Trials Alliance. “Collaborating with Ora not only improves outcomes for historically underrepresented patient populations but provides an opportunity to explore new and innovative ways to increase clinical trial access for all patients. Europe is in a position to accelerate getting drugs to market faster, while simultaneously helping to build a robust and sustainable clinical research ecosystem beyond the US", she continued.
About Ora, Inc.
Ora is the world's leading full-service ophthalmic drug and device development firm with offices in North America, South America, Europe, Australia, and Asia. For over 45 years, we have proudly helped our clients earn more than 82 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives. For more information, please visit www.oraclinical.com, like us on Facebook, and follow us on LinkedIn
Ora® and Ora Logo are registered trademarks of Ora, Inc.
About North West London Clinical Trials Alliance
The North West London Clinical Trials Alliance is dedicated to delivering commercial and non-commercial sponsored clinical trials – utilising existing and purpose-designed facilities to successfully deliver both early and late-phase research. It aims to increase regional capacity for delivering commercial clinical research, as well as to improve the ease and speed of research delivery, patient access to clinical research and patient opportunities for early access to cutting edge treatment and therapies that are not yet widely available through the NHS. This will be achieved through collaborative working, using our understanding of the needs and priorities of life science companies and our strong regional team ethos to work in a harmonised manner across centres. The ophthalmology unit at London North West University Healthcare NHS Trust, which is part of the North West London Clinical Trials Alliance, is recognised nationally as one of the leaders in delivery of commercial trials and is committed to widening access to novel and innovative treatments for the UK’s diverse communities to improve on health outcomes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712806839/en/
Contact information
Media
Claire Russell
crussell@oraclinical.com
+1 (919) 597-9029
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano Reports Record First-Quarter Revenue9.5.2025 03:12:00 EEST | Press release
Suzano, the world’s largest pulp producer, announces its first quarter results for 2025 (1Q25) with record net revenue of R$11.6 billion, up 22% on the same quarter last year (1Q24). The result was driven by the exchange rates, increased pulp sales volumes from the new Ribas do Rio Pardo mill, higher paper volume and prices and the positive contribution from our paperboard mills recently acquired in the U.S. The record revenues occurred despite a series of planned downtimes in the quarter, including production lines of the Três Lagoas Unit, Mucuri Unit, and Aracruz Unit, and the Ribas do Rio Pardo Unit’s first scheduled maintenance downtime. Sales exceeded 3 million tonnes in the quarter, a rise of 12% compared to 1Q24, comprising 2.7 million tonnes of pulp and 390 thousand tonnes of paper, up 10% and 25%, respectively, on the same quarter last year. Adjusted EBITDA totaled R$4.9 billion, a 7% increase over 1Q24. Operating cash generation totaled R$2.6 billion, rising 5% on 1Q24. Net p
GC Aesthetics® Strengthens Board of Directors with Strategic Appointments8.5.2025 18:10:00 EEST | Press release
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets is pleased to announce the appointment of Mr. Luigi Ferrari as Chairman of the Board (non-executive) and Mr. Patrick Lee as Board Director, reinforcing the company’s strategic direction and long-term growth plans. These appointments follow the renewed phase of partnership initiated in early 2024 with Hayfin Capital Management, a longstanding investor in GCA. This collaboration has brought fresh momentum to the company’s commitment to innovation, safety, and global expansion in aesthetic and reconstructive breast surgery. Luigi Ferrari, a seasoned executive and investor with a proven track record in the healthcare sector, brings deep leadership experience, commercial growth expertise and industry insight. From 2012 to 2022 he was CEO of Lima Corporate, a global medical device company in the joint replacement market, acquired then by Enovis Corp
PPG to invest $380 million to build new U.S. manufacturing facility in Shelby, N.C. for aerospace coatings and sealants8.5.2025 17:30:00 EEST | Press release
PPG (NYSE: PPG) today announced that it will invest $380 million to build a new aerospace coatings and sealants manufacturing facility in Shelby, N.C. Construction on the 62-acre site, which will initially include manufacturing and warehousing units, is set to commence in October 2025 and is expected to be completed in the first half of 2027. The 198,000-square-foot facility will enable the company to continue meeting the growing demands of the aerospace industry. It will employ more than 110 people and produce the full line of PPG’s aerospace coatings and sealants. The additional capacity of this new plant, combined with nearby transport links that improve supply chain and shipping logistics, will help improve service levels for customers. “PPG’s investment in this new manufacturing facility demonstrates the significant demand growth for our world-class technologies and our continued commitment to serving our aerospace customers,” said Tim Knavish, PPG chairman and chief executive off
WHOOP Unveils WHOOP® 5.0 and WHOOP® MG: Powerful New Devices with Breakthrough Health and Longevity Features8.5.2025 17:00:00 EEST | Press release
WHOOP, the human performance company, today introduces WHOOP 5.0 and WHOOP MG — two next-generation wearables designed to unlock a new approach to personal health and longevity. Paired with a redesigned WHOOP experience, the devices offer 14-day battery life in a sleeker, seven percent smaller form - and introduce category-defining features, including Healthspan with WHOOP Age, Heart Screener with on-demand ECG, Blood Pressure Insights, and more. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508546933/en/ WHOOP Unveils Next Generation WHOOP® 5.0 and WHOOP® MG These innovations arrive at a pivotal moment when ailing health systems cost more and deliver less. WHOOP is advancing a new solution and a better way - one that empowers people to connect their daily decisions to performance and health outcomes that can be measured and felt. While others track surface-level trends, WHOOP delivers longevity through depth — translati
Seoul Semiconductor Closes in on OSRAM for Global No.28.5.2025 16:00:00 EEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a leading global innovator of LED products and technology, announced that it has achieved a remarkable milestone by maintaining stable growth despite a downturn in the LED industry, narrowing the market share gap with global No.2 player ams OSRAM to just 1 percentage point. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508658995/en/ "2024 Global LED Market Share Rankings" (Source: Omdia) (Image: Seoul Semiconductor) According to the recently published “2024 Global LED Market Share Rankings” by market research firm Omdia, Seoul Semiconductor was the only company among the global top three to sustain both revenue and market share, while industry leaders Nichia and ams OSRAM experienced significant revenue declines amid the market slowdown. This achievement is underpinned by Seoul Semiconductor’s robust technological competitiveness, driven by its commitment to innovation even
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom